Cibus (CBUS)
Develops crop traits through gene editing and licenses them to seed companies.
Something off on this page? Send us feedback.
Develops productivity traits for major row crops using the RTDS and Trait Machine processes. Rather than sell seed, Cibus adapts traits to a customer's elite variety and licenses them for royalties.
Uses RTDS and the Trait Machine process to develop productivity traits for major row crops. Its commercial model edits a cell from a seed company's existing variety, regenerates a plant with the requested trait, and licenses the resulting trait for royalties instead of selling seed.
Development work spans canola, rice, soybean, wheat, and alfalfa, including herbicide-tolerance work in rice and a bio-based fermentation biofragrance program.
Commercial activities sit in one reportable segment and remain a trait-development and licensing pipeline rather than a mature product-revenue portfolio. Commercialization depends on scaling high-quality plants and seed cost-effectively, crop acceptance and performance within seed and downstream systems, regulatory treatment of gene-edited products, commodity-market conditions, and capital availability.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $20.4M · Total debt $32.7M · Total assets $313.4M · Shareholders' equity $14.8M
- Revenue
- $994.0K
- Operating income
- −$12.9M
- Net income
- −$22.1M
No dividends on record.
| Institutions | 24.23% | 18.52M shares | |
|---|---|---|---|
| 62 holders · as of Jun 30, 2026 | |||
| Insiders | 24.06% | 18.39M shares | |
| 10 holders · as of Jun 10, 2026 | |||
| Other | 51.71% | 39.52M shares | |
| remainder | |||
76.43M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Rory B. RiggsInsiderdirector, 10 percent owner | 19.52% | 14.92M | filed Feb 2, 2026 |
FMR LLCInstitution | 14.98% | 11.45M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.01% | 2.30M | as of Jun 30, 2026 |
Craig WichnerInsiderofficer: CEO | 1.17% | 894,309 | filed Jun 10, 2026 |
Jean-Pierre Jules LehmannInsiderdirector | 1.00% | 763,904 | filed Jun 4, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 13, 2025 | Noel Sauer | officer: Sr VP, Research | −4 | $1.49 |
